Prostate-specific membrane antigen PET in prostate cancer

C Lawhn-Heath, A Salavati, SC Behr, SP Rowe… - Radiology, 2021 - pubs.rsna.org
Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceuticals are playing a
large role at the time of initial staging and biochemical recurrence for localizing prostate …

[HTML][HTML] [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review

F Bois, C Noirot, S Dietemann, IC Mainta… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity

K Current, C Meyer, CE Magyar, CE Mona… - Clinical Cancer …, 2020 - AACR
Purpose: Prostate-specific membrane antigen (PSMA) targeting radioligands deliver
radiation to PSMA-expressing cells. However, the relationship between PSMA levels and …

The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer

P Deegen, O Thomas, O Nolan-Stevaux, S Li… - Clinical Cancer …, 2021 - AACR
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a disease with
high unmet medical need, as most patients do not achieve durable response with available …

Tunable multivalent platform for immune recruitment to lower antigen expressing cancers

BPM Lake, RG Wylie, C Bařinka… - Angewandte Chemie …, 2023 - Wiley Online Library
Chemical immunotherapeutic strategies including Antibody Recruiting Molecules (ARMs‐
bivalent small molecules containing an antibody‐binding domain (ABD) and a target …

[HTML][HTML] Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

K Lückerath, L Wei, WP Fendler, S Evans-Axelsson… - EJNMMI research, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA)-directed radioligand therapy
(RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer …

[HTML][HTML] Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy

L Widjaja, RA Werner, E Krischke… - European Journal of …, 2023 - Springer
Purpose γ-H2AX and 53BP1 are fundamental for cellular DNA damage response (DDR)
after radiation exposure and are linked to cell repair, arrest, or apoptosis. We aimed to …

Preclinical evaluation of 213Bi-and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer

SR Banerjee, A Lisok, I Minn, A Josefsson… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy is a new
option for patients with advanced prostate cancer refractory to other treatments. Previously …

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [18F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model

SB Kim, IH Song, SY Kim, HY Ko, HS Kil… - Molecular …, 2022 - ACS Publications
Several radiolabeled prostate-specific membrane antigen (PSMA)-targeted agents have
been developed for detecting prostate cancer, using positron emission tomography imaging …

[HTML][HTML] Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer

S Piron, J Verhoeven, E De Coster, B Descamps… - Scientific Reports, 2021 - nature.com
This two-part preclinical study aims to evaluate prostate specific membrane antigen (PSMA)
as a valuable target for expression-based imaging applications and to determine changes in …